Prime

Type your tag names separated by a space and hit enter

Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.

Abstract

INTRODUCTION

Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models.

METHODS

Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B).

RESULTS

In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3).

CONCLUSIONS

This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan; Department of Neurology, Juntendo University Koshigaya Hospital, Japan.

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan.

    ,

    School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan.

    ,

    Department of Neurology, Juntendo University School of Medicine, Japan.

    ,

    School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.

    ,

    School of Bioscience and Biotechnology, Tokyo University of Technology, Japan.

    ,

    Department of Neurology, Higashi Nagoya National Hospital, Japan.

    Department of Neurology, Juntendo University School of Medicine, Japan. Electronic address: nhattori@juntendo.ac.jp.

    Source

    Parkinsonism & related disorders 21:8 2015 Aug pg 911-6

    MeSH

    Aged
    Antioxidants
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    Neuroprotective Agents
    Parkinson Disease
    Pilot Projects
    Treatment Outcome
    Ubiquinone

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    26054881

    Citation

    TY - JOUR T1 - Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. AU - Yoritaka,Asako, AU - Kawajiri,Sumihiro, AU - Yamamoto,Yorihiro, AU - Nakahara,Toshiki, AU - Ando,Maya, AU - Hashimoto,Kazuhiko, AU - Nagase,Midori, AU - Saito,Yufuko, AU - Hattori,Nobutaka, Y1 - 2015/05/29/ PY - 2015/1/4/received PY - 2015/5/25/revised PY - 2015/5/27/accepted PY - 2015/5/29/aheadofprint PY - 2015/6/10/entrez PY - 2015/6/10/pubmed PY - 2016/5/7/medline KW - Complex I KW - Oxidative stress KW - Parkinson's disease KW - Randomized controlled trial KW - Reduced form of coenzyme Q10 SP - 911 EP - 6 JF - Parkinsonism & related disorders JO - Parkinsonism Relat. Disord. VL - 21 IS - 8 N2 - INTRODUCTION: Mitochondrial complex I deficiencies have been found in post-mortem brains of patients with Parkinson's disease (PD). Coenzyme Q10 (CoQ10) is the electron acceptor found in complexes I and II, and is a potent antioxidant. A recent trial of the oxidized form of CoQ10 for PD failed to show benefits; however, the reduced form of CoQ10 (ubiquinol-10) has shown better neuroprotective effects in animal models. METHODS: Randomized, double-blind, placebo-controlled, parallel-group pilot trials were conducted to assess the efficacy of ubiquinol-10 in Japanese patients with PD. Participants were divided into two groups: PD experiencing wearing off (Group A), and early PD, without levodopa (with or without a dopamine agonist) (Group B). Participants took 300 mg of ubiquinol-10 or placebo per day for 48 weeks (Group A) or 96 weeks (Group B). RESULTS: In Group A, total Unified Parkinson's Disease Rating Scale (UPDRS) scores decreased in the ubiquinol-10 group (n = 14; mean ± SD [-4.2 ± 8.2]), indicating improvement in symptoms. There was a statistically significant difference (p < 0.05) compared with the placebo group (n = 12; 2.9 ± 8.9). In Group B, UPDRS increased in the ubiquinol-10 group (n = 14; 3.9 ± 8.0), as well as in the placebo group (n = 8; 5.1 ± 10.3). CONCLUSIONS: This is the first report showing that ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and that ubiquinol-10 is safe and well tolerated. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/26054881/full_citation L2 - http://linkinghub.elsevier.com/retrieve/pii/S1353-8020(15)00240-0 ER -